middle.news
Prescient Therapeutics Secures $3M to Advance Cancer Therapy Trials
4:16am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Prescient Therapeutics Secures $3M to Advance Cancer Therapy Trials
4:16am on Saturday 30th of August, 2025 AEST
Key Points
Completed $3 million share placement with 11.25 million shares issued at 4 cents each
Funding secured from sophisticated professional investors
Supports ongoing clinical trials of PTX-100 and cell therapy platforms
Issued cleansing notice under section 708A of the Corporations Act
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Prescient Therapeutics (ASX:PTX)
OPEN ARTICLE